GLENMARK.NS Cash Flow
Glenmark Pharmaceuticals Ltd.
Profit & Loss Balance Sheet Cash Flow
Cash Flow · 4 years on file
(FY2022-23 to FY2025-26)
· fetched 2026-08-23 22:31
| Line item | FY2022-23 | FY2023-24 | FY2024-25 | FY2025-26 | Source (XBRL element) |
|---|---|---|---|---|---|
| Net Cash from Operating Activities | ₹625.39 Cr. | ₹-265.44 Cr. | ₹-827.60 Cr. | ₹3,445.03 Cr. | CashFlowsFromUsedInOperatingActivities |
| Net Cash from Investing Activities | ₹-528.49 Cr. | ₹4,369.14 Cr. | ₹2.09 Cr. | ₹-1,283.23 Cr. | CashFlowsFromUsedInInvestingActivities |
| Net Cash from Financing Activities | ₹-77.46 Cr. | ₹-3,906.13 Cr. | ₹787.04 Cr. | ₹-2,708.75 Cr. | CashFlowsFromUsedInFinancingActivities |
| Effect of Exchange Rate Changes | ₹13.05 Cr. | ₹17.68 Cr. | ₹55.89 Cr. | ₹45.96 Cr. | EffectOfExchangeRateChangesOnCashAndCashEquivalents |
| Net Increase/(Decrease) in Cash | ₹32.50 Cr. | ₹215.24 Cr. | ₹17.44 Cr. | ₹-501.00 Cr. | IncreaseDecreaseInCashAndCashEquivalents |
| Cash and Cash Equivalents (Closing) | ₹1,410.53 Cr. | ₹1,443.03 Cr. | N/A | N/A | CashAndCashEquivalentsCashFlowStatement |
Every figure above is the exact value of the named XBRL element from GLENMARK.NS's cached filing for that year — nothing here is estimated or backfilled. A company shows one column per year StockProof actually has data for — never padded with blank years. Rows shown as N/A are genuinely not disclosed under that year's filing format (see peer comparison for how other Healthcare companies compare).